102 kr
Läs direkt efter köp
Suzanne Hill – författare
Visar alla böcker från författaren Suzanne Hill. Handla med fri frakt och snabb leverans.
7 produkter
7 produkter
- Häftad, Engelska, 2020
310 kr
Skickas inom 3-6 vardagar
- E-bokPDF, Engelska, 2008
1 592 kr
Läs direkt efter köp
"The challenge in all settings is to make the difficult decisions in a way that is defensible, justifiable, ethical, and equitable"
So write Nick Freemantle and Suzanne Hill in their introduction to this important discussion on decision making in the reimbursement of pharmaceuticals. Based around a programme supported by the World Health Organization, chapters by leading academics involved in the research tackle such major issues as international pharmaceutical policy, tensions in licensing policies, priority setting, and relationships between the stakeholders.
Chapters include:
Development of marketing authorisation procedures for pharmaceuticals Interpreting clinical evidence International pharmaceutical policy: health creation or wealth creation? Development of fourth hurdle policies around the world Economic modelling in drug reimbursement Priority setting in health care: matching decision criteria with policy objectives Tensions in licensing and reimbursement decisions: case of riluzole for amytrophic lateral sclerosis Relationship between stakeholders: managing the war of words Medicine and the media: good information or misleading hype? How to promote quality use of cost-effective medicines Using economic evaluation to inform health policy and reimbursement: making it happen and making it sustainable Pricing of pharmaceuticals Evaluating pharmaceuticals for health policy in low and middle income country settings.Besides the controversial issues there is a wealth of practical information including economic modelling and the experiences from the WHO programme, providing readers with workable examples. This is essential reading for clinical researchers in pharmaceuticals and policy makers everywhere.
- Inbunden, Engelska, 2015
573 kr
Skickas inom 10-15 vardagar
This book is intended to communicate current best practice in pediatric clinical pharmacology and clinical pharmacy with special consideration of the prevailing circumstances and most pressing needs in developing countries. It also addresses measures that may be taken in countries with emerging economies through organizational and political adjustments to reduce unacceptable levels of morbidity and mortality among children and pregnant women with treatable diseases. - E-bokPDF, Engelska, 2015
739 kr
Läs direkt efter köp
This book is intended to communicate current best practice in pediatric clinical pharmacology and clinical pharmacy with special consideration of the prevailing circumstances and most pressing needs in developing countries. It also addresses measures that may be taken in countries with emerging economies through organizational and political adjustments to reduce unacceptable levels of morbidity and mortality among children and pregnant women with treatable diseases.
- Häftad, Engelska, 2016
573 kr
Skickas inom 10-15 vardagar
This book is intended to communicate current best practice in pediatric clinical pharmacology and clinical pharmacy with special consideration of the prevailing circumstances and most pressing needs in developing countries. It also addresses measures that may be taken in countries with emerging economies through organizational and political adjustments to reduce unacceptable levels of morbidity and mortality among children and pregnant women with treatable diseases. - Häftad, Engelska, 2004
1 042 kr
Tillfälligt slut
"The challenge in all settings is to make the difficult decisions in a way that is defensible, justifiable, ethical, and equitable"So write Nick Freemantle and Suzanne Hill in their introduction to this important discussion on decision making in the reimbursement of pharmaceuticals. Based around a programme supported by the World Health Organization, chapters by leading academics involved in the research tackle such major issues as international pharmaceutical policy, tensions in licensing policies, priority setting, and relationships between the stakeholders.Chapters include: Development of marketing authorisation procedures for pharmaceuticalsInterpreting clinical evidenceInternational pharmaceutical policy: health creation or wealth creation?Development of fourth hurdle policies around the worldEconomic modelling in drug reimbursementPriority setting in health care: matching decision criteria with policy objectivesTensions in licensing and reimbursement decisions: case of riluzole for amytrophic lateral sclerosisRelationship between stakeholders: managing the war of wordsMedicine and the media: good information or misleading hype?How to promote quality use of cost-effective medicinesUsing economic evaluation to inform health policy and reimbursement: making it happen and making it sustainablePricing of pharmaceuticalsEvaluating pharmaceuticals for health policy in low and middle income country settings.Besides the controversial issues there is a wealth of practical information including economic modelling and the experiences from the WHO programme, providing readers with workable examples. This is essential reading for clinical researchers in pharmaceuticals and policy makers everywhere.
